Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 29:12:863.
doi: 10.3332/ecancer.2018.863. eCollection 2018.

Surgery for BRCA, TP53 and PALB2: a literature review

Chin-Vern Song  1 , Soo-Hwang Teo  1 , Nur Aishah Taib  2 , Cheng-Har Yip  3
Affiliations
Review

Surgery for BRCA, TP53 and PALB2: a literature review

Chin-Vern Song et al. Ecancermedicalscience. .

Abstract

Introduction: The presence of a deleterious mutation, most commonly a BRCA mutation, has a tremendous impact on the management of breast cancer. We review the surgical management of BRCA mutation carriers, and two other potentially high-risk mutations, TP53 and PALB2.

Methodology: A search was done on PubMed, limited to reviews and the English language only. The search terms used were 'BRCA' or 'PALB2' or 'TP53' and 'surgery'. Fifteen articles were identified by searching and one article was obtained from other sources.

Results: Breast-conserving surgery has equivalent survival, but may have an increased risk of local recurrence, compared to mastectomy among BRCA mutation carriers. Contralateral prophylactic mastectomy may not improve overall survival, despite reducing the risk of developing contralateral breast cancer. The use of preoperative genetic testing allows patients to have combined curative and prophylactic surgery. However, preoperative genetic testing may influence patients to make rash decisions. In healthy BRCA mutation carriers, bilateral prophylactic mastectomy is done to prevent breast cancer from occurring. Bilateral prophylactic mastectomy is highly effective in reducing the risk of breast cancer in healthy BRCA mutation-positive women and may have a survival benefit. Prophylactic oophorectomy reduces the risk of ovarian cancer, but may not have an effect on the risk of breast cancer. There is a lack of studies on surgery for non-BRCA mutations. TP53 and PALB2 are potentially high-risk mutations for breast cancer, which may justify the use of prophylactic surgery. Advice should be given on a case-by-case basis.

Conclusion: A comprehensive approach is needed to provide optimum treatment for breast cancer patients with deleterious mutations.

Keywords: breast cancer; genetic mutations; surgery.

PubMed Disclaimer

References

    1. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291–1299. - PMC - PubMed
    1. Heisey RE, Carroll JC, Warner E, et al. Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers. Can Fam Physician. 1999;45:114–124. - PMC - PubMed
    1. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372(23):2243–2257. doi: 10.1056/NEJMsr1501341. - DOI - PMC - PubMed
    1. Jonasson JG, Stefansson OA, Johannsson OT, et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer. 2016;115(7):776–783. doi: 10.1038/bjc.2016.249. - DOI - PMC - PubMed
    1. Heil J, Fuchs V, Golatta M, et al. Extent of primary breast cancer surgery: standards and individualized concepts. Breast Care (Basel) 2012;7(5):364–369. doi: 10.1159/000343976. - DOI - PMC - PubMed

LinkOut - more resources